Finerenone in Heart Failure: Clinical Application and Benefits

Primary Indication and Dosing

• The American Diabetes Association recommends finerenone for adults with type 2 diabetes and chronic kidney disease (CKD) who have persistent albuminuria, with eGFR ≥25 mL/min/1.73 m² and serum potassium <4.8 mEq/L, at a dose of 10-20 mg once daily 1, 2
• Finerenone should be started at 10 mg once daily if eGFR 25-60 mL/min/1.73 m², or 20 mg once daily if eGFR >60 mL/min/1.73 m², with serum potassium checked at baseline and after 4 weeks 2

Cardiovascular Benefits

• Finerenone reduces heart failure hospitalization by 29% (HR 0.71, 95% CI 0.56-0.90) in patients with type 2 diabetes and CKD 3
• Finerenone reduces composite cardiovascular outcomes (CV death, nonfatal MI, nonfatal stroke, or HF hospitalization) by 13-14% (HR 0.86-0.87) in patients with type 2 diabetes and CKD 4, 5

Therapeutic Positioning

• The American Diabetes Association guidelines establish a clear hierarchy for cardiorenal protection, with SGLT2 inhibitors or GLP-1 receptor agonists as first-line, and finerenone as second-line for patients with persistent albuminuria 4, 5
• The American Heart Association supports combining finerenone with SGLT2 inhibitors for potentially additive benefits 1

Safety Monitoring

• Hyperkalemia is the primary adverse effect requiring vigilant monitoring, with an incidence of 10.8-14% with finerenone vs. 5.3-6.9% with placebo 3
• Severe hyperkalemia requiring discontinuation occurs in only 1.2-1.7% of patients 2, 3